0001062993-22-010574.txt : 20220420 0001062993-22-010574.hdr.sgml : 20220420 20220420182204 ACCESSION NUMBER: 0001062993-22-010574 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20220419 FILED AS OF DATE: 20220420 DATE AS OF CHANGE: 20220420 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I, L.P. CENTRAL INDEX KEY: 0001695076 STATE OF INCORPORATION: E9 FISCAL YEAR END: 0331 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 22839220 BUSINESS ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (345) 949 1040 MAIL ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 FORMER NAME: FORMER CONFORMED NAME: Pivotal Venture Partners Fund I, L.P. DATE OF NAME CHANGE: 20170118 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I G.P., L.P. CENTRAL INDEX KEY: 0001752862 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 22839219 BUSINESS ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 697-1002 MAIL ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Pivotal bioVenture Partners Fund I U.G.P., Ltd CENTRAL INDEX KEY: 0001752847 STATE OF INCORPORATION: E9 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39397 FILM NUMBER: 22839218 BUSINESS ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 BUSINESS PHONE: (415) 697-1002 MAIL ADDRESS: STREET 1: 501 SECOND STREET, SUITE 200 CITY: SAN FRANCISCO STATE: CA ZIP: 94107 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Inozyme Pharma, Inc. CENTRAL INDEX KEY: 0001693011 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 475129768 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 BUSINESS PHONE: 857-330-4340 MAIL ADDRESS: STREET 1: 321 SUMMER STREET STREET 2: SUITE 400 CITY: BOSTON STATE: MA ZIP: 02210 FORMER COMPANY: FORMER CONFORMED NAME: Inozyme Pharma, LLC DATE OF NAME CHANGE: 20161222 4 1 form4.xml STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES X0306 4 2022-04-19 0001693011 Inozyme Pharma, Inc. INZY 0001695076 Pivotal bioVenture Partners Fund I, L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 1 0 0 0 0001752862 Pivotal bioVenture Partners Fund I G.P., L.P. 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 1 0 0 0 0001752847 Pivotal bioVenture Partners Fund I U.G.P., Ltd 501 SECOND STREET, SUITE 200 SAN FRANCISCO CA 94107 1 0 0 0 Common Stock 2022-04-19 4 P 0 1070000 3.69 A 2661154 I See footnotes The reportable securities are owned directly by Pivotal bioVenture Partners Fund I, L.P. ("Pivotal"). The general partner of Pivotal is Pivotal bioVenture Partners Fund I G.P., L.P. ("Pivotal GP"). The general partner of Pivotal GP is Pivotal bioVenture Partners Fund I U.G.P., Ltd (the "Ultimate General Partner"). The Ultimate General Partner is wholly-owned by Pivotal Partners Ltd ("Pivotal Partners"). Pivotal Partners is wholly-owned by Pivotal Life Sciences Holdings Limited ("Pivotal Life Sciences"). Pivotal Life Sciences is wholly-owned by Nan Fung Life Sciences Holdings Limited ("Nan Fung Life Sciences"), and Nan Fung Life Sciences is wholly owned by NF Investment Holdings LImited ("NFIHL"), which is wholly owned by Nan Fung Group Holdings Limited ("NFGHL"). The members of the Executive Committee of NFGHL make investment decisions with respect to the securities of the Issuer held by Pivotal. Mr. Kam Chung Leung, Mr. Frank Kai Shui Seto, Mr. Vincent Sai Sing Cheung, Mr. Pui Kuen Cheung, Mr. Kin Ho Kwok, Ms. Vanessa Tih Lin Cheung, Mr. Meng Gao and Mr. Chun Wai Nelson Tang are the members of the Executive Committee of NFGHL. Robert Hopfner, a managing partner of the Ultimate General Partner, is a member of the board of directors of the Issuer. Such person's and entities disclaim beneficial ownership over such securities except to the extent of any pecuniary interest therein. /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I, L.P., as Managing Partner 2022-04-20 /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I G.P., L.P., as Managing Partner 2022-04-20 /s/ Robert Hopfner - for Pivotal bioVenture Partners Fund I U.G.P., Ltd, as Managing Partner 2022-04-20